ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31

ALX ONCOLOGY HOLDINGS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.14+0.08 (+7.55%)

Close on Oct 19, 2026

Market cap: $154.63M
P/E (TTM): –
Dividend yield: –

ALX ONCOLOGY HOLDINGS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31
Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0.53	0.66	1.21	1.26	1.30	–
Research & Development	13	14	18	17	18	24	24	26	35	32	42	46	29	25	25	29	27	17	21	18	11	9.85	12	5.33	7.66	3.83	6.74	2.21	3.63	–
General & Administrative	5.13	5.36	5.38	5.09	5.45	7.93	7.08	6.10	6.87	6.05	6.24	7.51	7.30	7.44	7.02	7.30	7.04	7.67	7.58	6.36	5.09	4.36	5.68	4.48	3.17	1.47	1.11	0.94	0.68	–
Operating Expenses	18	19	23	23	27	32	31	33	42	38	48	53	37	32	32	37	34	25	28	25	16	14	18	9.81	11	5.90	8.95	4.29	5.48	5.26
Operating Income	-18	-19	-23	-23	-27	-32	-31	-33	-42	-38	-48	-53	-37	-32	-32	-37	-34	-25	-28	-25	-16	-14	-18	-9.81	-11	-5.24	-7.73	-3.03	-4.19	–
Interest Expense	0.29	0.33	0.38	0.41	0.41	0.41	0.43	0.45	0.43	0.43	0.42	0.39	0.37	0.39	0.23	0.00	0.00	0.00	–	–	–	–	–	0.30	0.20	–	–	–	–	–
Interest & Investment Income	1.51	1.18	0.57	0.80	1.11	1.48	1.88	2.30	2.56	2.62	3.00	2.68	2.67	2.31	1.81	1.37	0.88	0.23	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.26	0.19	-0.02	-0.01	0.00	-0.01	0.00	0.00	-0.01	-0.01	-0.03	0.00	0.32	0.10	0.00	-0.01	-0.01	-0.01	0.01	-0.01	0.00	0.00	-0.93	-0.11	-0.31	0.01	–	–	–	–
Asset Impairment Charges	–	0	0	0	3.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	–	–	0	0	–
Gain (Loss) on Sale of Assets	-0.20	–	–	–	–	–	0	0	0	-0.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-28	-25	-16	-14	-19	-10	-11	-5.45	-7.76	-3.04	-4.19	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.18	0.04	0.02	0.00	0.01	0.01	0.01	–
Net Income incl. Noncontrolling Interests	-18	-18	-23	-22	-26	-31	-29	-31	-39	-36	-45	-51	-34	-30	-31	-35	-33	-25	-28	-25	-16	-14	-19	-10	-11	-5.45	-7.76	-3.04	–	–
Net Income	-18	-18	-23	-22	-26	-31	-29	-31	-39	-36	-45	-51	-34	-30	-31	-35	-33	-25	-28	-25	-16	-14	-19	-10	-11	-5.45	-7.76	-3.04	-4.20	-4.24
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.58	2.64	1.98	1.07	1.07	0.98	–
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-28	-25	-16	-14	-19	-11	-14	-7.44	-8.84	-4.12	-5.18	-5.14
EPS (Basic)(per share)	-0.13	-0.17	-0.42	-0.41	-0.49	-0.58	-0.54	-0.58	-0.76	-0.71	-0.93	-1.24	-0.84	-0.74	-0.75	-0.87	-0.81	-0.60	-0.70	-0.61	-0.40	-0.35	–	-0.36	-4.41	-2.37	-2.83	-1.33	-1.68	–
EPS (Diluted)(per share)	-0.13	-0.17	-0.42	-0.41	-0.49	-0.58	-0.54	-0.58	-0.76	-0.71	-0.93	-1.24	-0.84	-0.74	-0.75	-0.87	-0.81	-0.60	-0.70	-0.61	-0.40	-0.35	–	-0.36	-4.41	-2.37	-2.83	-1.33	-1.68	–
Shares Outstanding (Basic, Weighted)(shares)	136	105	54	54	53	53	54	53	52	50	49	41	41	41	41	41	41	41	41	40	40	40	–	30	3.16	3.14	3.12	3.10	3.09	–
Shares Outstanding (Diluted, Weighted)(shares)	136	105	54	54	53	53	54	53	52	50	49	41	41	41	41	41	41	41	41	40	40	40	–	30	3.16	3.14	3.12	3.10	3.09	–
EBITDA	-18	-19	-23	-22	-26	-32	-30	-32	-41	-38	-48	-53	-37	-32	-32	-37	-34	-25	-28	-25	-16	-14	-18	-9.71	-11	-5.13	-7.62	-2.93	-4.09	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -145.7%

Financial strength

Current ratio: 9.71
Debt to equity: 0.07
Debt to assets: 6.0%
Cash to current liabilities: 153.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.14
Dividend yield: –